A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 18 Apr 2018 Status changed from active, no longer recruiting to discontinued.
- 03 Jan 2018 Planned End Date changed from 31 Dec 2017 to 31 Mar 2018.
- 18 Aug 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.